Drug Development

Cerebrospinal fluid levels of a hormone called vasopressin were lower in babies who went on to develop autism than in those who did not, a study found.

With no approved treatments for COVID-19, Stanford Medicine has joined large-scale clinical trials to determine if remdesivir, an experimental anti-viral medication, works.

The researchers also identified a molecular pathway involved in turning back the clock on the cells. Drugs that could manipulate the pathway might be an effective substitute for exercise, they suggest.

Stanford’s test for COVID-19, caused by the novel coronavirus, is rapidly expanding capacity to serve patients in the Bay Area and beyond. Researchers hope to soon be able to process more than 1,000 tests per day.

Screening thousands of drugs, Stanford scientists determined that in mice, azlocillin, an antibiotic approved by the Food and Drug Administration, eliminated the bacteria that causes Lyme disease.

The Stanford Clinical Virology Laboratory has deployed an in-house diagnostic test for the virus that causes COVID-19. Rapid identification of infected people could help limit the spread of the virus.

Stanford researchers have found that drug-coated nanoparticles limit the development of atherosclerosis in mice, without side effects.

An effort to thwart viral diseases like hepatitis or the common cold led to a new collaboration and a novel class of cancer drugs that appears effective in mice.

In a speech at Stanford, National Cancer Institute Director Norman Sharpless reported promising cancer mortality trends and described an encouraging landscape for research funding and drug approval.